Additional Relevant Details "Raptor Pharmaceuticals announced that they have signed a definitive agreement with Tripex Pharmaceuticals to acquire the first inhaled fluoroquinolone approved for the management of chronic pulmonary infections due to Pseudomonas Aeruginosa in adults with cystic fibrosis. The drug is marketed under the name Quinsair, and helps expand Raptor's portfolio of rare disease therapies. Quinsair is already approved in Europe and Canada, and the company plans to discuss the path to approval for the same indication with the FDA in 2016.
""Quinsair is an important new addition to the options that we can offer adult European and Canadian CF patients today,"" stated Patrick Flume, M.D., Professor of Medicine and Pediatrics at the Medical University of South Carolina. ""Since it is a new class of inhaled antibiotics, Quinsair's availability is an important step in addressing an unmet need for the CF community. I'm especially excited about the possibilities to broaden the availability of a drug like this for patients with non-CF bronchiectasis and pulmonary nontuberculous mycobacterial infections, for whom there are limited treatment options.""